GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

As 2025 ushers in a new era of weight loss resolutions, many Americans are abandoning traditional gym-first approaches in ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?